Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell–cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis

Cytotherapy

Volumn 18, Issue 9, 2016, Pages 1162-1177

  Mu, Ying ^a   Zhou, Chang Hui ^a   Chen, Shuang Feng ^a   Ding, Jie ^a   Zhang, Ying Xin ^a   Yang, Ya Pei ^a   Wang, Wei Hua ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

cytokine induced killer cells; dendritic cells; gastric cancer; immunotherapy; meta analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CHINA; CLINICAL EFFECTIVENESS; CNKI DATABASE; COCHRANE LIBRARY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FEVER; FEVER; HUMAN; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER DYSFUNCTION; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; WANFANG DATABASE; BIOLOGICAL THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; STOMACH TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL- AND TISSUE-BASED THERAPY; CHINA; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE SUBSETS; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84990065763     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.015     Document Type: Article

References (70)

1. [1] McGuire, S., World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7:2 (2016), 418–419, 10.3945/an.116.012211.
2. [2] Chen, W., Zheng, R., Zeng, H., Zhang, S., He, J., Annual report on status of cancer in China, 2011. Chin J Cancer Res 27:1 (2015), 2–12, 10.3978/j.issn.1000-9604.2015.01.06.
3. [3] Galvao de Azevedo, I., Leal Muniz Carneiro, I.C., Oliveira Tomiya, M.T., Pessoa de Araujo Burgos, M.G., Gastric cancer and associated factors in hospitalized patients. Nutr Hosp 32:1 (2015), 283–290, 10.3305/nh.2015.32.1.9071.
4. [4] Kalnina, Z., Meistere, I., Kikuste, I., Tolmanis, I., Zayakin, P., Line, A., Emerging blood-based biomarkers for detection of gastric cancer. World J Gastroenterol 21:41 (2015), 11636–11653, 10.3748/wjg.v21.i41.11636.
5. [5] Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480:7378 (2011), 480–489, 10.1038/nature10673.
6. [6] Thanendrarajan, S., Nowak, M., Abken, H., Schmidt-Wolf, I.G., Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res 35:9 (2011), 1136–1142, 10.1016/j.leukres.2011.05.005.
7. [7] Dudley, M.E., Gross, C.A., Somerville, R.P., Hong, Y., Schaub, N.P., Rosati, S.F., et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:17 (2013), 2152–2159, 10.1200/JCO.2012.46.6441.
8. [8] Zhao, Z., Liao, H., Ju, Y., Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy. J Tradit Chin Med 36:1 (2016), 14–18.
9. [9] Chia, W.K., Teo, M., Wang, W.W., Lee, B., Ang, S.F., Tai, W.M., et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22:1 (2014), 132–139, 10.1038/mt.2013.242.
10. [10] Shi, L., Zhou, Q., Wu, J., Ji, M., Li, G., Jiang, J., et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61:12 (2012), 2251–2259, 10.1007/s00262-012-1289-2.
11. [11] Restifo, N.P., Dudley, M.E., Rosenberg, S.A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:4 (2012), 269–281, 10.1038/nri3191.
12. [12] Sangiolo, D., Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2 (2011), 363–368.
13. [13] Wang, Z.X., Cao, J.X., Liu, Z.P., Cui, Y.X., Li, C.Y., Li, D., et al. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol 20:4 (2014), 1095–1106, 10.3748/wjg.v20.i4.1095.
14. [14] Chen, B., Liu, L., Xu, H., Yang, Y., Zhang, L., Zhang, F., Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. Exp Ther Med 9:3 (2015), 1063–1067, 10.3892/etm.2015.2217.
15. [15] Zhu, X.P., Xu, Y.H., Zhou, J., Pan, X.F., A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res 14:3 (2015), 10228–10235, 10.4238/2015.August.28.6.
16. [16] Mao, Q., Li, L., Zhang, C., Sun, Y., Liu, S., Cui, S., Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci 28:3 Suppl. (2015), 1055–1058.
17. [17] Lin, T., Song, C., Chuo, D.Y., Zhang, H., Zhao, J., Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biol 37 (2015), 4367–4372, 10.1007/s13277-015-3957-2.
18. [18] Kakimi, K., Nakajima, J., Wada, H., Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65:1 (2009), 1–8, 10.1016/j.lungcan.2008.10.018.
19. [19] Jakel, C.E., Schmidt-Wolf, I.G., An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther 14:7 (2014), 905–916, 10.1517/14712598.2014.900537.
20. [20] Olioso, P., Giancola, R., Di Riti, M., Contento, A., Accorsi, P., Iacone, A., Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 27:3 (2009), 130–139, 10.1002/hon.886.
21. [21] Mehta, B.A., Schmidt-Wolf, I.G., Weissman, I.L., Negrin, R.S., Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 86:9 (1995), 3493–3499.
22. [22] Li, G.X., Zhao, S.S., Zhang, X.G., Wang, W.H., Liu, J., Xue, K.W., et al. Comparison of the proliferation, cytotoxic activity and cytokine secretion function of cascade primed immune cells and cytokine-induced killer cells in vitro. Mol Med Rep 12:2 (2015), 2629–2635, 10.3892/mmr.2015.3765.
23. [23] Zhong, R., Han, B., Zhong, H., A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 35:2 (2014), 987–994, 10.1007/s13277-013-1132-1.
24. [24] Gonzalez-Carmona, M.A., Marten, A., Hoffmann, P., Schneider, C., Sievers, E., Schmidt-Wolf, I.G., et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26:3 (2006), 369–379, 10.1111/j.1478-3231.2005.01235.x.
25. [25] Hadzantonis, M., O'Neill, H., Review: dendritic cell immunotherapy for melanoma. Cancer Biother Radiopharm 14:1 (1999), 11–22, 10.1089/cbr.1999.14.11.
26. [26] Steinman, R.M., Nussenzweig, M.C., Dendritic cells: features and functions. Immunol Rev 53 (1980), 127–147.
27. [27] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3:3 (2009), e123–30.
28. [28] Zeng, X., Zhang, Y., Kwong, J.S., Zhang, C., Li, S., Sun, F., et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8:1 (2015), 2–10, 10.1111/jebm.12141.
29. [29] Han, R.X., Liu, X., Pan, P., Jia, Y.J., Yu, J.C., Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLoS ONE, 9(9), 2014, e108958, 10.1371/journal.pone.0108958.
30. [30] Wu, S., Keresztes, R.S., Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest 29:7 (2011), 460–471, 10.3109/07357907.2011.597815.
31. [31] Kautio, A.L., Haanpaa, M., Kautiainen, H., Leminen, A., Kalso, E., Saarto, T., Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res 31:10 (2011), 3493–3496.
32. [32] Jackson, D., White, I.R., Riley, R.D., Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31:29 (2012), 3805–3820, 10.1002/sim.5453.
33. [33] Chen, Y., Guo, Z.Q., Shi, C.M., Zhou, Z.F., Ye, Y.B., Chen, Q., Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int J Clin Exp Med 8:5 (2015), 7728–7736.
34. [34] Cui, Y., Bai, B., Wen, Y., Kuang, S., [Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 17:7 (2014), 698–701.
35. [35] Fan, Y.L., Zhao, H., Yu, J.P., Li, H., Ren, B.Z., Cao, S., et al. Clinical efficacy of chemotherapy combined with cytokine-induced killer cell treatment after curative resection for gastric cancer patients. Chin J Cancer Biother 19:2 (2012), 168–174.
36. [36] Fu, D.P., Li, L., Han, D.Y., Clinical efficacy of dendritic cells combined with cytokine killer cells in treatment of elderly patients with advanced gastric cancer. Clin J Med Offic 43:2 (2015), 132–135.
37. [37] Gao, D., Li, C., Xie, X., Zhao, P., Wei, X., Sun, W., et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS ONE, 9(4), 2014, 10.1371/journal.pone.0093886 e93886.
38. [38] Jiang, J.T., Shen, Y.P., Wu, C.P., Zhu, Y.B., Wei, W.X., Chen, L.J., et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 16:48 (2010), 6155–6162.
39. [39] Jiang, J., Xu, N., Wu, C., Deng, H., Lu, M., Li, M., et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26:3b (2006), 2237–2242.
40. [40] Liu, H., Song, J., Yang, Z., Zhang, X., Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 6:4 (2013), 953–956, 10.3892/etm.2013.1247.
41. [41] Lv, G., Zhang, Q.-J., Shi, Y.-Q., Cao, Z.-Y., Clinical observation of chemotherapy combined with autologous cytokine-induced killer cells and dendritic cells for advanced gastric cancer. Med J Chin PLA 40:6 (2015), 475–478.
42. [42] Shan, H.H., Huang, G.Q., Clinical efficacy of DC-CIK combined with chemotherapy in the treatment of 45 cases patients with advanced gastric cancer. Chin J Gastroenterol Hepatol 23:12 (2014), 1416–1419.
43. [43] Shi, L., Zhou, Q., Wu, J., Ji, M., Li, G., Jiang, J., et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61:12 (2012), 2251–2259.
44. [44] Sun, M.F., Ding, Z.Y., Liu, Z.Z., Zheng, Z.D., Piao, Y., Guo, F., et al. Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced gastric cancer: a randomized control study. Mod Oncol 21:7 (2013), 1537–1540.
45. [45] Wu, F.B., Huang, W., Wang, K.X., Wang, M.Y., Xu, F.G., Huang, C.K., et al. Study on DC-CIK combined with chemotherapy in the treatment of patients with advanced gastric cancer. Mod J Integr Tradition Chin West Med 24:3 (2015), 242–244.
46. [46] Xu, Q.X., Chang, Z.G., Zhang, X.D., Ma, L., He, L.M., The observation of curative effects on the treatment of advanced gastric cancer by CIK cells combined with Docetaxel, Oxaliplation and S-1. Chin J Cancer Biother 22:3 (2015), 381–384.
47. [47] Zhang, Y., Yi, S.M., Wu, Z.X., Efficacy of cytokine induced killer cells with dendritic cells biological treatment and chemotherapy for patients with gastric cancer underwent surgery. Chin J Clin Oncol Rehabil 22:12 (2015), 1412–1415.
48. [48] Zhang, Y., Liu, J.B., Yang, L., Clinical estimtation of effects on chemotherapy combined with CIK for patients with advanced gastric cancer. J Basic Clin Oncol 22:4 (2009), 346–348.
49. [49] Zhao, H., Fan, Y., Li, H., Yu, J., Liu, L., Cao, S., et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm 28:4 (2013), 303–309, 10.1089/cbr.2012.1306.
50. [50] Peoples, G.E., Gurney, J.M., Hueman, M.T., Woll, M.M., Ryan, G.B., Storrer, C.E., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:30 (2005), 7536–7545, 10.1200/JCO.2005.03.047.
51. [51] Lee, J.H., Lim, Y.S., Yeon, J.E., Song, T.J., Yu, S.J., Gwak, G.Y., et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148:7 (2015), 1383–1391, 10.1053/j.gastro.2015.02.055 e6.
52. [52] Linn, Y.C., Niam, M., Chu, S., Choong, A., Yong, H.X., Heng, K.K., et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 47:7 (2012), 957–966, 10.1038/bmt.2011.202.
53. [53] Introna, M., Pievani, A., Borleri, G., Capelli, C., Algarotti, A., Mico, C., et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 16:11 (2010), 1603–1607, 10.1016/j.bbmt.2010.05.015.
54. [54] Introna, M., Borleri, G., Conti, E., Franceschetti, M., Barbui, A.M., Broady, R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92:7 (2007), 952–959.
55. [55] Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., Negrin, R.S., A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:3 (2005), 181–187, 10.1016/j.bbmt.2004.11.019.
56. [56] Beavis, P.A., Slaney, C.Y., Kershaw, M.H., Neeson, P.J., Darcy, P.K., Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 7:5 (2015), 499–512, 10.2217/imt.15.16.
57. [57] Wang, Z.X., Cao, J.X., Wang, M., Li, D., Cui, Y.X., Zhang, X.Y., et al. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy 16:7 (2014), 934–945, 10.1016/j.jcyt.2014.02.011.
58. [58] Zhu, Y., Zhang, H., Li, Y., Bai, J., Liu, L., Liu, Y., et al. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. Cancer Immunol Immunother 62:10 (2013), 1629–1635, 10.1007/s00262-013-1465-z.
59. [59] Milasiene, V., Stratilatovas, E., Norkiene, V., The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients. Medicina (Kaunas) 43:7 (2007), 548–554.
60. [60] Cho, M.Y., Joh, Y.G., Kim, N.R., Jung, S.I., Bae, J.W., Kim, Y.C., et al. T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg 91:2 (2002), 172–177.
61. [61] Dulos, J., Carven, G.J., van Boxtel, S.J., Evers, S., Driessen-Engels, L.J., Hobo, W., et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35:2 (2012), 169–178, 10.1097/CJI.0b013e318247a4e7.
62. [62] Luo, M., Liang, X., Luo, S.T., Wei, X.W., Liu, T., Ren, J., et al. Folate-modified lipoplexes delivering the interleukin-12 gene for targeting colon cancer immunogene therapy. J Biomed Nanotechnol 11:11 (2015), 2011–2023.
63. [63] Atan, O., Aksu, G., Ozgenc, F., Akman, S.A., Karaca, N.E., Sertoz, R., et al. Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha. Turk J Gastroenterol 21:4 (2010), 401–410.
64. [64] Wei, X.C., Yang, D.D., Han, X.R., Zhao, Y.A., Li, Y.C., Zhang, L.J., et al. Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect. Int J Clin Exp Med 8:10 (2015), 19725–19730.
65. [65] Schmidt, J., Eisold, S., Buchler, M.W., Marten, A., Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 53:11 (2004), 1018–1026, 10.1007/s00262-004-0554-4.
66. [66] Ge, W., Li, C.H., Zhang, W., Han, Q., Deng, W.M., Chen, L., et al. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo]. Zhonghua Xue Ye Xue Za Zhi 25:5 (2004), 277–280.
67. [67] Wang, Q.J., Wang, H., Pan, K., Li, Y.Q., Huang, L.X., Chen, S.P., et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 29:7 (2010), 641–648.
68. [68] Tsiatas, M.L., Gritzapis, A.D., Cacoullos, N.T., Papadhimitriou, S.I., Baxevanis, C.N., Papamichail, M., A novel culture environment for generating mature human dentritic cells from peripheral blood CD14+ cells. Anticancer Res 21:2A (2001), 1199–1206.
69. [69] Marten, A., Renoth, S., von Lilienfeld-Toal, M., Buttgereit, P., Schakowski, F., Glasmacher, A., et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86:10 (2001), 1029–1037.
70. [70] Li, H., Ren, X.B., Zhang, P., An, X.M., Liu, H., Hao, X.S., [Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells]. Zhonghua Yi Xue Za Zhi 85:44 (2005), 3134–3138.